Puma Biotechnology | PBYI - Przychody Ze Sprzedaży





Obroty Zmiana Data
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Daiichi Sankyo JPY 574.74B 12.26B 2026-06
Exelixis USD 628.69M 17.89M 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Moderna USD 100M 289M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 15.03B 530M 2026-06
PTC Therapeutics USD 361M 88M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Takeda JPY 1.22T 130B 2026-06
TG Therapeutics USD 240.34M 45.54M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 3.33B 340M 2026-06